Abstract:// Dennis Ruder 1, 2 , Vassiliki Papadimitrakopoulou 4 , Kazuhiko Shien 2 , Carmen Behrens 4 , Neda Kalhor 5 , Huiqin Chen 6 , Li Shen 3 , J. Jack Lee 6 , Waun Ki Hong 4 , Ximing Tang 2 , Luc Girard 7 , John D. Minna 7 , Lixia Diao 3 , Jing Wang 3 , Barbara Mino 2 , Pamela Villalobos 2 , Jaime Rodriguez-Canales 2 , Nana E. Hanson 2 , James Sun 9 , Vincent Miller 9 , Joel Greenbowe 9 , Garrett Frampton 9 , Roy S. Herbst 8 , Veera Baladandayuthapani 6 , Ignacio I. Wistuba 2 and Julie G. Izzo 2 1 Graduate Program in Human and Molecular Genetics and Cancer Biology, MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, Texas, USA 2 Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 3 Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 4 Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 5 Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 6 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA 7 Hamon Center for Therapeutic Oncology Research, The University of Texas Southwestern Medical Center, Dallas, Texas, USA 8 Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut, USA 9 Foundation Medicine, Inc., Cambridge, Massachusetts, USA Correspondence to: Julie G. Izzo, email: jizzo@mdanderson.org Ignacio I. Wistuba, email: iiwistuba@mdanderson.org Keywords: RICTOR gene abnormalities; KRAS mutation; MAPK pathway; mTORC2; non-small cell lung cancer Received: April 13, 2018 Accepted: September 09, 2018 Published: September 21, 2018 ABSTRACT Despite a therapeutic paradigm shift into targeted-driven medicinal approaches, resistance to therapy remains a hallmark of lung cancer, driven by biological and molecular diversity. Using genomic and expression data from advanced non-small cell lung cancer (NSCLC) patients enrolled in the BATTLE-2 clinical trial, we identified RICTOR alterations in a subset of lung adenocarcinomas and found RICTOR expression to carry worse overall survival. RICTOR-altered cohort was significantly enriched in KRAS/MAPK axis mutations, suggesting a co-oncogenic driver role in these molecular settings. Using NSCLC cell lines, we showed that, distinctly in KRAS mutant backgrounds, RICTOR blockade impairs malignant properties and generates a compensatory enhanced activation of the MAPK pathway, exposing a unique therapeutic vulnerability. In vitro and in vivo concomitant pharmacologic inhibition of mTORC1/2 and MEK1/2 resulted in synergistic responses of anti-tumor effects. Our study provides evidence of a distinctive therapeutic opportunity in a subset of NSCLC carrying concomitant RICTOR/KRAS alterations.

Supplemental Figure 2 from KDR Amplification is Associated with VEGF-Induced Activation of the Mtor and Invasion Pathways but Does Not Predict Clinical Benefit to the VEGFR TKI Vandetanib

KDR Amplification is Associated with VEGF-Induced Activation of the Mtor and Invasion Pathways but Does Not Predict Clinical Benefit to the VEGFR TKI Vandetanib.

Supplementary Figure 3 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Altered Regulation of HIF-1α in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype.

Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of -altered non-small cell lung cancer.

Supplementary Figure 4 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Supplementary Figure 5 from an Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl As a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Supplemental Figure 2 from Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma

Supplemental Figures and Tables from the HGF/c-MET Pathway is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer

Data from the HGF/c-MET Pathway is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer

Supplementary Figure S14 from Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non–Small Cell Lung Cancer

Supplementary Figure S2 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC

Supplementary Figure S10 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC

Supplementary Figure S1 from Comutations and KRAS<sup>G12C</sup> Inhibitor Efficacy in Advanced NSCLC

Supplementary Figure 1 from Increased VEGFR-2 Gene Copy Is Associated with Chemoresistance and Shorter Survival in Patients with Non–Small-Cell Lung Carcinoma Who Receive Adjuvant Chemotherapy

Supplementary Figure 1 from Mtor Inhibitors Block Kaposi Sarcoma Growth by Inhibiting Essential Autocrine Growth Factors and Tumor Angiogenesis

Fig S1 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

Supplementary Figure 1 from Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling

Supplemental Figure 4 from IKBKE is a Substrate of EGFR and a Therapeutic Target in Non–Small Cell Lung Cancer with Activating Mutations of EGFR

Supplementary Figure 2 from Mutations in BRAF and KRAS Converge on Activation of the Mitogen-Activated Protein Kinase Pathway in Lung Cancer Mouse Models

Phase 2 trial of regorafenib in recurrent or metastatic adenoid cystic carcinoma